PE20190624A1 - 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2 - Google Patents
3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2Info
- Publication number
- PE20190624A1 PE20190624A1 PE2019000035A PE2019000035A PE20190624A1 PE 20190624 A1 PE20190624 A1 PE 20190624A1 PE 2019000035 A PE2019000035 A PE 2019000035A PE 2019000035 A PE2019000035 A PE 2019000035A PE 20190624 A1 PE20190624 A1 PE 20190624A1
- Authority
- PE
- Peru
- Prior art keywords
- pirazinas
- metil
- rent
- trisustituidas
- shp2
- Prior art date
Links
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title abstract 2
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 208000005101 LEOPARD Syndrome Diseases 0.000 abstract 1
- 206010062901 Multiple lentigines syndrome Diseases 0.000 abstract 1
- 206010029748 Noonan syndrome Diseases 0.000 abstract 1
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/26—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 3-METIL-PIRAZINAS 2,5-DISUSTITUIDAS Y 3-METIL-PIRAZINAS 2,5,6-TRISUSTITUIDAS DE FORMULA (I-W) DONDE A ES CICLOALQUILO, HETEROCICLOALQUILO, ARILO O HETEROARILO; Y1 ES -S-, UN ENLACE DIRECTO, -NH-, -S(O)2-, ENTRE OTROS; Y2 ES -C(O)-, -C(O)O-, -OC(O)-, ENTRE OTROS; R1 ES -H, -ALQUILO C1-C6, -ALQUENILO C2-C6, ENTRE OTROS; R2 ES -OH, -CN, -ALQUILO C1-C6, ENTRE OTROS; R3 ES -H, -ALQUILO C1-C6, UN ESPIROHETEROCICLO DE 5 A 12 MIEMBROS, ENTRE OTROS; R4 ES -H, -ALQUILO C1-C6, -HALOALQUILO C1-C6, ENTRE OTROS; n ES DE 0 A 10. SON COMPUESTOS PREFERIDOS: (R)-8-(5-((2,3-DICLOROFENIL)TIO)-6-FENILPIRAZIN-2-IL)-8-AZASPIRO[4,5]DECAN-1-AMINA; (R)-8-(6-CICLOPROPIL-5-((2,3-DICLOROPIRIDIN-4-IL)TIO)PIRAZIN-2-IL)-8-AZASPIRO[4,5]DECAN-1-AMINA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE LA PROTEINA TIROSINA FOSFATASA-2 (SHP2) SIENDO UTIL EN EL TRATAMIENTO DEL SINDROME DE NOONAN, SINDROME LEOPARD, LEUCEMIAS MIELOMONOCITICAS JUVENILES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662361249P | 2016-07-12 | 2016-07-12 | |
US201762449523P | 2017-01-23 | 2017-01-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190624A1 true PE20190624A1 (es) | 2019-04-26 |
Family
ID=59383648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019000035A PE20190624A1 (es) | 2016-07-12 | 2017-07-11 | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2 |
Country Status (22)
Country | Link |
---|---|
US (3) | US10590090B2 (es) |
EP (2) | EP4302834A2 (es) |
JP (3) | JP6916279B2 (es) |
KR (2) | KR102598895B1 (es) |
CN (3) | CN116478132A (es) |
AU (3) | AU2017296289A1 (es) |
BR (1) | BR112019000494A2 (es) |
CA (1) | CA3030167A1 (es) |
CL (1) | CL2019000090A1 (es) |
CO (1) | CO2019000613A2 (es) |
CR (1) | CR20190063A (es) |
DO (1) | DOP2019000005A (es) |
EC (1) | ECSP19010079A (es) |
IL (1) | IL264186B1 (es) |
MA (1) | MA45660A (es) |
MX (2) | MX2019000548A (es) |
PE (1) | PE20190624A1 (es) |
PH (1) | PH12019500056A1 (es) |
SG (1) | SG11201900157RA (es) |
TN (1) | TN2019000010A1 (es) |
TW (1) | TWI806832B (es) |
WO (1) | WO2018013597A1 (es) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
EP4108659A1 (en) | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
EP3681879A1 (en) | 2017-09-11 | 2020-07-22 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
EP3694848A1 (en) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
EP3724189B1 (en) | 2017-12-15 | 2023-10-04 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
WO2019158019A1 (zh) | 2018-02-13 | 2019-08-22 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
CN110655520A (zh) * | 2018-06-29 | 2020-01-07 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
CN110156786B (zh) * | 2018-02-13 | 2022-06-03 | 青煜医药研发(上海)有限公司 | 嘧啶并环化合物及其制备方法和应用 |
EP3768668A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
AU2019251207A1 (en) | 2018-04-10 | 2020-11-19 | Revolution Medicines, Inc. | SHP2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations |
BR112020022224A2 (pt) | 2018-05-02 | 2021-06-08 | Navire Pharma, Inc. | inibidores heterocíclicos substituídos de ptpn11 |
SG11202100199UA (en) | 2018-08-10 | 2021-02-25 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
CN112839935A (zh) * | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
JP7386855B2 (ja) | 2018-09-29 | 2023-11-27 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物及び組成物の製造 |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
WO2020076723A1 (en) | 2018-10-08 | 2020-04-16 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
TW202028183A (zh) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
PE20211465A1 (es) | 2018-10-17 | 2021-08-05 | Array Biopharma Inc | Inhibidores de la proteina tirosina fosfatasa |
CN109265352B (zh) * | 2018-10-31 | 2021-06-04 | 杭州迈世腾药物科技有限公司 | 芳基环丙基醚及其衍生物的制备方法 |
TW202039498A (zh) | 2018-11-30 | 2020-11-01 | 大陸商上海拓界生物醫藥科技有限公司 | 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用 |
WO2020156242A1 (zh) * | 2019-01-31 | 2020-08-06 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
SG11202109036WA (en) | 2019-03-01 | 2021-09-29 | Revolution Medicines Inc | Bicyclic heteroaryl compounds and uses thereof |
MX2021010323A (es) | 2019-03-01 | 2021-12-10 | Revolution Medicines Inc | Compuestos bicíclicos de heterociclilo y usos de este. |
CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药(苏州)有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
CN113795483A (zh) * | 2019-03-07 | 2021-12-14 | 默克专利有限公司 | 作为shp2拮抗剂的甲酰胺-嘧啶衍生物 |
CA3135555C (en) * | 2019-04-02 | 2023-09-19 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
CN113646049A (zh) | 2019-04-08 | 2021-11-12 | 默克专利有限公司 | 作为shp2拮抗剂的嘧啶酮衍生物 |
CN114190090A (zh) | 2019-06-07 | 2022-03-15 | 锐新医药公司 | Shp2抑制剂{6-[(2-氨基-3-氯吡啶-4-基)硫烷基]-3-[(3s,4s)-4-氨基-3-甲基-2-氧杂-8-氮杂螺[4.5]癸烷-8-基]-5-甲基吡嗪-2-基}甲醇的固体形式 |
AU2020306124A1 (en) | 2019-06-28 | 2022-02-03 | Tuojie Biotech (Shanghai) Co., Ltd. | Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof |
CN111704611B (zh) * | 2019-07-25 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类芳基螺环类shp2抑制剂化合物、制备方法和用途 |
CN112300160A (zh) * | 2019-08-01 | 2021-02-02 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物、其制备及应用 |
EP3772513A1 (en) | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
WO2021043077A1 (zh) * | 2019-09-06 | 2021-03-11 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
WO2021061515A1 (en) * | 2019-09-23 | 2021-04-01 | Synblia Therapeutics, Inc. | Shp2 inhibitors and uses thereof |
CA3154862A1 (en) | 2019-09-24 | 2021-04-01 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
WO2021076655A1 (en) | 2019-10-15 | 2021-04-22 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
CA3160142A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
WO2021091982A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
EP4069301A1 (en) | 2019-12-04 | 2022-10-12 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
EP4087611A1 (en) | 2020-01-07 | 2022-11-16 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
CN114867720A (zh) | 2020-01-16 | 2022-08-05 | 浙江海正药业股份有限公司 | 杂芳基类衍生物及其制备方法和用途 |
CN113135910A (zh) | 2020-01-19 | 2021-07-20 | 北京诺诚健华医药科技有限公司 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
WO2021147879A1 (zh) * | 2020-01-21 | 2021-07-29 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
EP4110338A1 (en) | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
CN113493440A (zh) * | 2020-04-03 | 2021-10-12 | 上海翰森生物医药科技有限公司 | 含氮杂芳类衍生物的盐及其晶型 |
TW202144334A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜芳類衍生物游離鹼的晶型 |
WO2021218752A1 (en) * | 2020-04-26 | 2021-11-04 | Betta Pharmaceuticals Co., Ltd | Shp2 inhibitors, compositions and uses thereof |
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
JP2023530838A (ja) | 2020-06-22 | 2023-07-20 | スーチュアン・コールン-バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | 置換されたピラジン化合物、当該化合物を含む医薬組成物、及びその使用 |
CN116113418A (zh) * | 2020-08-25 | 2023-05-12 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物及其制备方法和用途 |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
JP2023549055A (ja) | 2020-10-27 | 2023-11-22 | アムジエン・インコーポレーテツド | 複素環式スピロ化合物及びその使用方法 |
KR20230171917A (ko) * | 2020-12-18 | 2023-12-21 | 젠자임 코포레이션 | Shp2 억제제를 제조하는 방법 |
CA3203111A1 (en) | 2020-12-22 | 2022-06-30 | Kailiang Wang | Sos1 inhibitors and uses thereof |
WO2022161222A1 (zh) * | 2021-01-29 | 2022-08-04 | 四川科伦博泰生物医药股份有限公司 | 一类杂环类shp2抑制剂、其制备方法及用途 |
EP4039685A1 (en) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
CN117083285A (zh) * | 2021-03-31 | 2023-11-17 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
EP4067358A1 (en) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
JP2024517693A (ja) | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 2-アミノベンゾチアゾール化合物及びその使用方法 |
CN117177752A (zh) | 2021-05-05 | 2023-12-05 | 诺华股份有限公司 | 用于治疗mpnst的化合物和组合物 |
EP4333850A1 (en) * | 2021-05-05 | 2024-03-13 | Huyabio International, LLC | Shp2 inhibitor monotherapy and uses thereof |
IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
KR20240004960A (ko) | 2021-05-05 | 2024-01-11 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ras阻害剤及びその使用 |
CN114716448B (zh) * | 2021-05-13 | 2024-01-30 | 中国科学院上海药物研究所 | 抑制shp2活性的杂环化合物、其制备方法及用途 |
CN115368373A (zh) | 2021-05-21 | 2022-11-22 | 石药集团中奇制药技术(石家庄)有限公司 | 螺环类化合物及其用途 |
TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
CN113636952B (zh) * | 2021-07-19 | 2023-07-21 | 河南农业大学 | 一种制备4-溴苯甲酰胺的方法 |
WO2023018155A1 (ko) * | 2021-08-09 | 2023-02-16 | 주식회사 유빅스테라퓨틱스 | Shp2 단백질 분해활성을 갖는 화합물 및 이들의 의약 용도 |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023046198A1 (zh) * | 2021-09-27 | 2023-03-30 | 中国医药研究开发中心有限公司 | 磺胺酮类化合物及其制备方法和医药用途 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023122938A1 (en) * | 2021-12-28 | 2023-07-06 | Js Innomed Holdings Ltd. | Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
WO2023159086A1 (en) | 2022-02-16 | 2023-08-24 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
WO2023159087A1 (en) | 2022-02-16 | 2023-08-24 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023169170A1 (zh) * | 2022-03-10 | 2023-09-14 | 捷思英达控股有限公司 | 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 |
WO2023180245A1 (en) | 2022-03-21 | 2023-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of shp2 inhibitors for inhibiting senescence |
TW202402761A (zh) * | 2022-03-28 | 2024-01-16 | 美商健臻公司 | 製備shp2抑制劑的方法 |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024015360A1 (en) | 2022-07-11 | 2024-01-18 | Amgen Inc. | Methods of treating cancer |
WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
EP4345101A1 (en) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
WO2024085699A1 (ko) * | 2022-10-19 | 2024-04-25 | 주식회사 유빅스테라퓨틱스 | Shp2 단백질 분해용 화합물 및 이들의 의약 용도 |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2572728A (en) * | 1949-01-07 | 1951-10-23 | American Cyanamid Co | Hydroxybenzenesulfonamidopyra-zines and preparation of same |
US2636882A (en) | 1950-08-11 | 1953-04-28 | Quaker Oats Co | Preparation of 3-pyridols from 2-acylfurans |
BE758503A (fr) | 1969-11-07 | 1971-05-05 | Shell Int Research | Compositions pesticides |
GB1459571A (en) | 1974-09-12 | 1976-12-22 | Pfizer Ltd | Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus |
JPS5762269A (en) * | 1980-10-03 | 1982-04-15 | Ogawa Koryo Kk | 2,3,5-trisubstituted pyrazine derivative |
US4513135A (en) * | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
JPH0249775A (ja) | 1988-05-19 | 1990-02-20 | Nippon Soda Co Ltd | 6員環又は7員環を有する複素環化合物及びその製造方法 |
JPH04112877A (ja) | 1990-09-04 | 1992-04-14 | Nippon Soda Co Ltd | 新規シアノピラジン誘導体及びその製造方法 |
EP0579835A4 (en) | 1991-11-12 | 1994-06-01 | Nippon Soda Co | Wavelength conversion material for agriculture |
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
WO1997029109A1 (en) | 1996-02-07 | 1997-08-14 | Janssen Pharmaceutica N.V. | Pyrazolopyrimidines as crf receptor antagonists |
CA2293400A1 (en) | 1997-06-13 | 1998-12-17 | Gerald Mcmahon | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
CA2382789A1 (en) | 1999-08-27 | 2001-03-08 | Sugen, Inc. | Phosphate mimics and methods of treatment using phosphatase inhibitors |
WO2001060806A2 (en) | 2000-02-16 | 2001-08-23 | Neurogen Corporation | Substituted arylpyrazines |
EP1448587B1 (en) | 2001-10-01 | 2009-09-02 | Mount Sinai School of Medicine | Noonan syndrome gene |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
EP1446387B1 (en) | 2001-11-21 | 2009-11-04 | Pharmacia & Upjohn Company LLC | Substituted aryl 1,4-pyrazine derivatives |
JP2005531520A (ja) | 2002-03-28 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | 置換2,3−ジフェニルピリジン類 |
CA2494975A1 (en) * | 2002-09-12 | 2004-03-25 | Pharmacia & Upjohn Company Llc | Substituted 1,4-pyrazine derivatives |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
JP2006525993A (ja) | 2003-05-09 | 2006-11-16 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | Crf1受容体拮抗剤である化合物 |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
WO2005028480A2 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
ATE369370T1 (de) | 2003-10-10 | 2007-08-15 | Pfizer Prod Inc | Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren |
RU2006118325A (ru) * | 2003-10-27 | 2007-12-10 | Астеллас Фарма Инк. (Jp) | Производные пиразина и их фармацевтическое применение |
DE102004015954A1 (de) * | 2004-04-01 | 2005-11-10 | Ina-Schaeffler Kg | Umschlingungstrieb |
JP4978192B2 (ja) | 2004-04-01 | 2012-07-18 | アステラス製薬株式会社 | ピラジン誘導体およびその医薬的使用 |
JP2008503591A (ja) | 2004-06-22 | 2008-02-07 | ライジェル ファーマシューティカルズ, インコーポレイテッド | ユビキチンリガーゼ阻害剤 |
CN101087767A (zh) | 2004-12-23 | 2007-12-12 | 马林克罗特公司 | 荧光吡嗪衍生物及其在评估肾功能中的使用方法 |
WO2006113704A2 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
BRPI0611863B1 (pt) | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
US20080274469A1 (en) | 2005-10-21 | 2008-11-06 | The Regents Of The University Of California | C-Kit Oncogene Mutations in Melanoma |
CN101267844A (zh) | 2006-02-24 | 2008-09-17 | 马林克罗特公司 | 使用光学试剂的方法 |
WO2007117699A2 (en) | 2006-04-07 | 2007-10-18 | University Of South Florida | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs |
AU2007243280A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
JP2009538877A (ja) | 2006-05-31 | 2009-11-12 | ガラパゴス・ナムローゼ・フェンノートシャップ | 変性疾患及び炎症性疾患の治療に有用なトリアゾロピラジン化合物 |
TW200808802A (en) | 2006-06-06 | 2008-02-16 | Schering Corp | Imidazopyrazines as protein kinase inhibitors |
EP2131861A2 (en) | 2007-03-01 | 2009-12-16 | Mallinckrodt Inc. | Integrated photoactive small molecules and uses thereof |
CN101679418A (zh) | 2007-04-06 | 2010-03-24 | 诺瓦提斯公司 | 用作蛋白质激酶抑制剂的[2,6]萘啶类化合物 |
US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
US8133895B2 (en) | 2007-05-10 | 2012-03-13 | Janssen Pharmaceutica N.V. | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
EP2157090A4 (en) | 2007-06-21 | 2011-09-07 | Taisho Pharmaceutical Co Ltd | PYRAZINAMIDVERBINDUNG |
US8003797B2 (en) | 2007-08-09 | 2011-08-23 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
US9174969B2 (en) | 2008-07-21 | 2015-11-03 | University Of South Florida | Indoline scaffold SHP-2 inhibitors and cancer treatment method |
JP2012507540A (ja) | 2008-10-30 | 2012-03-29 | メルク・シャープ・エンド・ドーム・コーポレイション | ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト |
DK2389372T3 (en) | 2009-01-23 | 2015-12-14 | Rigel Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR INHIBITION OF JAK pathway |
WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
EP2438041A4 (en) | 2009-06-01 | 2012-11-21 | Merck Sharp & Dohme | PYRAZINE-carboxamide-orexin receptor Antagonist |
MX353747B (es) * | 2009-08-17 | 2018-01-26 | Memorial Sloan Kettering Cancer Center Star | Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos. |
CA2780713A1 (en) | 2009-09-03 | 2011-03-10 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
RU2617966C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
EP2569304A1 (en) | 2010-05-11 | 2013-03-20 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
US8703768B2 (en) | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
ES2622519T3 (es) | 2010-07-14 | 2017-07-06 | Novartis Ag | Componentes heterocíclicos agonistas del receptor IP |
GB201106829D0 (en) * | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
US9127000B2 (en) | 2011-02-23 | 2015-09-08 | Intellikine, LLC. | Heterocyclic compounds and uses thereof |
WO2012149280A2 (en) | 2011-04-29 | 2012-11-01 | Abbott Laboratories | Novel tricyclic compounds |
CN103181918B (zh) | 2011-05-04 | 2014-10-29 | 厦门大学 | 脂肪酸类化合物在制备预防和治疗肝癌药物中的应用 |
WO2013105063A1 (en) * | 2012-01-13 | 2013-07-18 | Novartis Ag | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
ES2618004T3 (es) | 2012-08-07 | 2017-06-20 | Merck Patent Gmbh | Derivados de piridopirimidina como inhibidores de proteínas quinasas |
MX2015005812A (es) | 2012-11-08 | 2015-09-23 | Pfizer | Compuestos heteroaromaticos y su uso como ligandos de dopamina d1. |
WO2014085490A1 (en) | 2012-11-29 | 2014-06-05 | Chemocentryx, Inc. | Cxcr7 antagonists |
WO2014113584A1 (en) | 2013-01-16 | 2014-07-24 | Rhode Island Hospital | Compositions and methods for the prevention and treatment of osteolysis and osteoporosis |
CA2900303A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4 |
CN111139256A (zh) | 2013-02-20 | 2020-05-12 | 诺华股份有限公司 | 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症 |
PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
CN103554038B (zh) | 2013-06-19 | 2015-10-14 | 云南大学 | 多卤代苯腈喹唑啉酮化合物及其制备方法和用途 |
US10093646B2 (en) * | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
JP6473457B2 (ja) | 2014-01-17 | 2019-02-20 | ノバルティス アーゲー | Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物 |
JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
DK3174868T3 (da) | 2014-08-01 | 2021-11-08 | Nuevolution As | Forbindelser, der er aktive mod bromodomæner |
US10472347B2 (en) | 2014-11-18 | 2019-11-12 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
ES2881305T3 (es) | 2014-12-17 | 2021-11-29 | Siemens Healthcare Diagnostics Inc | Diseño de ensayo sandwich para pequeñas moléculas |
SG11201703880VA (en) | 2014-12-23 | 2017-07-28 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
EP4289950A3 (en) | 2015-01-09 | 2024-01-24 | Revolution Medicines, Inc. | Macrocyclic compounds that participate in cooperative binding and medical uses thereof |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
CN112625028A (zh) * | 2015-06-19 | 2021-04-09 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
US10426842B2 (en) | 2015-07-15 | 2019-10-01 | The Curators Of The University Of Missouri | Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug |
US9989535B2 (en) | 2015-10-01 | 2018-06-05 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
WO2017079723A1 (en) | 2015-11-07 | 2017-05-11 | Board Of Regents, The University Of Texas System | Targeting proteins for degradation |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
EP4108659A1 (en) | 2016-06-07 | 2022-12-28 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
EA036446B1 (ru) | 2016-06-14 | 2020-11-11 | Новартис Аг | Соединения и композиции для подавления активности shp2 |
CN116478132A (zh) | 2016-07-12 | 2023-07-25 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪 |
EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
AU2018207464B2 (en) | 2017-01-10 | 2020-05-14 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
AU2018239542C1 (en) | 2017-03-23 | 2021-02-11 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CA3058953A1 (en) | 2017-04-05 | 2018-10-11 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
BR112019020967A2 (pt) | 2017-04-05 | 2020-05-05 | Revolution Medicines Inc | métodos e reagentes para analisar interfaces de proteína-proteína |
US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
EP3694848A1 (en) | 2017-10-12 | 2020-08-19 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
EP3724189B1 (en) | 2017-12-15 | 2023-10-04 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric shp2 inhibitors |
CN110156786B (zh) | 2018-02-13 | 2022-06-03 | 青煜医药研发(上海)有限公司 | 嘧啶并环化合物及其制备方法和应用 |
WO2019158019A1 (zh) | 2018-02-13 | 2019-08-22 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
AU2019251207A1 (en) | 2018-04-10 | 2020-11-19 | Revolution Medicines, Inc. | SHP2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with SHP2 mutations |
PE20212112A1 (es) | 2018-05-01 | 2021-11-04 | Revolution Medicines Inc | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor |
CA3098698A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mtor inhibitors |
CA3111980A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
US11459340B2 (en) | 2018-09-18 | 2022-10-04 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as Src homology-2 phosphatase inhibitors |
WO2020076723A1 (en) | 2018-10-08 | 2020-04-16 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MX2021007468A (es) | 2018-12-21 | 2021-08-05 | Revolution Medicines Inc | Compuestos que participan en la union cooperativa y usos de los mismos. |
CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
-
2017
- 2017-07-11 CN CN202310285469.3A patent/CN116478132A/zh active Pending
- 2017-07-11 MX MX2019000548A patent/MX2019000548A/es unknown
- 2017-07-11 CN CN201780050842.XA patent/CN109983001B/zh active Active
- 2017-07-11 TN TNP/2019/000010A patent/TN2019000010A1/en unknown
- 2017-07-11 MA MA045660A patent/MA45660A/fr unknown
- 2017-07-11 SG SG11201900157RA patent/SG11201900157RA/en unknown
- 2017-07-11 CR CR20190063A patent/CR20190063A/es unknown
- 2017-07-11 EP EP23209237.9A patent/EP4302834A2/en active Pending
- 2017-07-11 TW TW106123173A patent/TWI806832B/zh active
- 2017-07-11 KR KR1020197004088A patent/KR102598895B1/ko active IP Right Grant
- 2017-07-11 EP EP17742609.5A patent/EP3484856B1/en active Active
- 2017-07-11 AU AU2017296289A patent/AU2017296289A1/en not_active Abandoned
- 2017-07-11 CA CA3030167A patent/CA3030167A1/en active Pending
- 2017-07-11 KR KR1020237037794A patent/KR20230156174A/ko active Application Filing
- 2017-07-11 BR BR112019000494-7A patent/BR112019000494A2/pt unknown
- 2017-07-11 WO PCT/US2017/041577 patent/WO2018013597A1/en unknown
- 2017-07-11 PE PE2019000035A patent/PE20190624A1/es unknown
- 2017-07-11 CN CN202310268752.5A patent/CN116478131A/zh active Pending
- 2017-07-11 IL IL264186A patent/IL264186B1/en unknown
- 2017-07-11 JP JP2019522611A patent/JP6916279B2/ja active Active
-
2018
- 2018-12-20 US US16/228,324 patent/US10590090B2/en active Active
-
2019
- 2019-01-08 DO DO2019000005A patent/DOP2019000005A/es unknown
- 2019-01-09 PH PH12019500056A patent/PH12019500056A1/en unknown
- 2019-01-11 CL CL2019000090A patent/CL2019000090A1/es unknown
- 2019-01-11 MX MX2022007607A patent/MX2022007607A/es unknown
- 2019-01-22 CO CONC2019/0000613A patent/CO2019000613A2/es unknown
- 2019-02-12 EC ECSENADI201910079A patent/ECSP19010079A/es unknown
-
2020
- 2020-06-18 US US16/905,884 patent/US11661401B2/en active Active
-
2021
- 2021-07-15 JP JP2021116788A patent/JP7416740B2/ja active Active
- 2021-11-30 AU AU2021277664A patent/AU2021277664B2/en active Active
-
2023
- 2023-03-21 US US18/124,352 patent/US20240116878A1/en active Pending
- 2023-10-13 JP JP2023177195A patent/JP2024009957A/ja active Pending
- 2023-11-16 AU AU2023266357A patent/AU2023266357A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190624A1 (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2 | |
PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
PE20090773A1 (es) | Derivados de morfolina pirimidina | |
PE20141828A1 (es) | 6-alquinilo piridinas como mimeticos smac | |
PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
PE20110419A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
MA42230A (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
PE20140690A1 (es) | Benzoxazepinonas fusionadas como moduladoras de canales ionicos | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
PE20201497A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih | |
CY1120325T1 (el) | Τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις φωσφοϊνοσιτιδιου 3-κινασης | |
PE20161225A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
PE20110387A1 (es) | Aminotriazolo-piridinas como inhibidores de cinasa | |
PE20090365A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa | |
EA201591176A1 (ru) | Композиции и способы с использованием пептидной метки, связывающейся с гиалуронаном | |
EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
PE20130405A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
PE20090237A1 (es) | Derivados de sulfonamidas como inhibidores de los canales de sodio | |
PE20130281A1 (es) | Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae | |
PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico |